Anti-SE6L2/ SEZ6L2/ BSRPA monoclonal antibody

Anti-SE6L2/ SEZ6L2/ BSRPA antibody for FACS & in-vivo assay

Target products collectionGo to SEZ6L2/SEZ6L2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1509-Ab-1/ GM-Tg-hg-MP1509-Ab-2Anti-Human SEZ6L2 monoclonal antibodyHuman
GM-Tg-rg-MP1509-Ab-1/ GM-Tg-rg-MP1509-Ab-2Anti-Rat SEZ6L2 monoclonal antibodyRat
GM-Tg-mg-MP1509-Ab-1/ GM-Tg-mg-MP1509-Ab-2Anti-Mouse SEZ6L2 monoclonal antibodyMouse
GM-Tg-cynog-MP1509-Ab-1/ GM-Tg-cynog-MP1509-Ab-2Anti-Cynomolgus/ Rhesus macaque SEZ6L2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1509-Ab-1/ GM-Tg-felg-MP1509-Ab-2Anti-Feline SEZ6L2 monoclonal antibodyFeline
GM-Tg-cang-MP1509-Ab-1/ GM-Tg-cang-MP1509-Ab-2Anti-Canine SEZ6L2 monoclonal antibodyCanine
GM-Tg-bovg-MP1509-Ab-1/ GM-Tg-bovg-MP1509-Ab-2Anti-Bovine SEZ6L2 monoclonal antibodyBovine
GM-Tg-equg-MP1509-Ab-1/ GM-Tg-equg-MP1509-Ab-2Anti-Equine SEZ6L2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1509-Ab-1/ GM-Tg-hg-MP1509-Ab-2; GM-Tg-rg-MP1509-Ab-1/ GM-Tg-rg-MP1509-Ab-2;
GM-Tg-mg-MP1509-Ab-1/ GM-Tg-mg-MP1509-Ab-2; GM-Tg-cynog-MP1509-Ab-1/ GM-Tg-cynog-MP1509-Ab-2;
GM-Tg-felg-MP1509-Ab-1/ GM-Tg-felg-MP1509-Ab-2; GM-Tg-cang-MP1509-Ab-1/ GM-Tg-cang-MP1509-Ab-2;
GM-Tg-bovg-MP1509-Ab-1/ GM-Tg-bovg-MP1509-Ab-2; GM-Tg-equg-MP1509-Ab-1/ GM-Tg-equg-MP1509-Ab-2
Products NameAnti-SEZ6L2 monoclonal antibody
Formatmab
Target NameSEZ6L2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SEZ6L2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SE6L2/ SEZ6L2/ BSRPA VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1509
    Target NameSEZ6L2
    Gene ID26470,233878,308988,707244,479784,101097532,505735,100065923
    Gene Symbol and SynonymsBSRP-A,BSRPA,PSK-1,Psk1,RGD1565281,SEZ6L2
    Uniprot AccessionQ6UXD5,Q29RN8
    Uniprot Entry NameSE6L2_HUMAN,SE6L2_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000174938
    Target ClassificationN/A

    The target: SEZ6L2, gene name: SEZ6L2, also named as BSRPA, PSK-1. This gene encodes a seizure-related protein that is localized on the cell surface. The gene is located in a region of chromosome 16p11.2 that is thought to contain candidate genes for autism spectrum disorders (ASD), though there is no evidence directly implicating this gene in ASD. Increased expression of this gene has been found in lung cancers, and the protein is therefore considered to be a novel prognostic marker for lung cancer. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Aug 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.